

Pipeline Product List-EU



Active Substance	Form	Strength	Therapeutical Use	Reference Product	Dossier Status
Levosimendan	Solution for Infusion- Vial	2.5MG/1ML (5ML)	Cardiac Stimulants	SIMDAX 2.5mg/ml Concentrate for Solution for Infusion marketed by Orion Pharma	Ready for Submission in Q3/2021
Ibrutinib	Capsule	140MG	Antineoplastic	IMBRUVICA 140mg Hard Capsules marketed by Janssen-Cilag International NV	Patent Expiration: 2030 Estimated Dossier Ready Date for Submission: 2026
Tofacitinib	Film-Ctd. Tablet	5MG&10MG	Immunosuppressant	XELJANZ 5mg&10mg Film-Coated Tablets marketed by Pfizer Europe MA EEIG	Patent Expiration: 2027 Estimated Dossier Ready Date for Submission: 2026
Pazopanib	Film-Ctd. Tablet	200MG&400MG	Antineoplastic	VOTRIENT 200mg&400mg Film Coated Tablets marketed by Novartis Europharm Limited	Patent Expiration: 2025 Estimated Dossier Ready Date for Submission: 2024
Apixaban	Film-Ctd. Tablet	2.5MG&5MG	Antithrombotic Agents	To Be Provided	Patent Expiration: 2026 Estimated Dossier Ready Date for Submission: Q1/2024
Golimubab	Solution for Injection-Prefilled Syringe (PFS)	50MG/0.5ML	Immunosuppressant	SIMPONI 45mg/0.45ml Solution for Injection in Pre-Filled Pen marketed by MSD	Patent Expiration: April/2025 Estimated Dossier Ready Date for Submission: 2024
Ranibizumab	Solution for Injection-Vial *For the Prefilled Syringe Form; the patent expiration date is 2033 and the estimated dossier ready date for submission is 2027	10MG/ML	Antineovascularisation Agents	LUCENTIS 10mg/ml Solution for Injection marketed by Novartis Pharma	Patent Expiration: July/2022 Estimated Dossier Ready Date for Submission: Q1/2022
Ferric Carboxymaltose	Solution for Injection-Vial	500MG/10ML	Anemia, Iron-Deficiency	FERINJECT IV Solution for Injection and Infusion 500mg/10ml marketed by Abdi İbrahim with the License of Vifor France SA Neuilly-sur-Seine	Patent Expiration: Expired Estimated Dossier Ready Date for Submission: Q1/2024